<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article article-type="other"><?properties open_access?><!-- Original-type: gg--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19127258</article-id><article-id pub-id-type="pmc">2634720</article-id><article-id pub-id-type="pii">6604847</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6604847</article-id><article-categories><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>A recurrent truncating germline mutation in the <italic>BRIP1</italic>/<italic>FANCJ</italic> gene and susceptibility to prostate cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf2">*</xref></contrib><contrib contrib-type="author"><name><surname>Jugurnauth</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mulholland</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Leongamornlert</surname><given-names>D A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Guy</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Edwards</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tymrakiewitcz</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>O'Brien</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wilkinson</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Al Olama</surname><given-names>A A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Morrison</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Muir</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Neal</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Donovan</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Hamdy</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Easton</surname><given-names>D F</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><collab>The UKGPCS Collaborators, The British Association of Urological Surgeons' Section of Oncology<sup>9</sup></collab></contrib><contrib contrib-type="author"><name><surname>Eeles</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Translational Cancer Genetics Team, The Institute of Cancer Research</institution> 15 Cotswold Road, Sutton, Surrey SM2 5NG, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>The Royal Marsden NHS Foundation Trust</institution> Downs Road, Sutton, Surrey SM2 5PT, and Fulham Road, London SW3 6JJ, <country>UK</country></aff><aff id="aff3"><label>3</label><institution>CR-UK Genetic Epidemiology Unit, University of Cambridge, Strangeways Laboratory</institution> Worts Causeway, Cambridge CB1 8RN, <country>UK</country></aff><aff id="aff4"><label>4</label><institution>University of Nottingham Medical School, Queens Medical Centre</institution> Nottingham NG7 2UH, <country>UK</country></aff><aff id="aff5"><label>5</label><institution>Surgical Oncology (Uro-Oncology: S4), Departments of Oncology and Surgery, University of Cambridge, Box 279, Addenbrooke's Hospital</institution> Hills Road, Cambridge CB2 2QQ, <country>UK</country></aff><aff id="aff6"><label>6</label><institution>Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre</institution> Robinson Way, Cambridge CB2 0RE, <country>UK</country></aff><aff id="aff7"><label>7</label><institution>Department of Social Medicine, University of Bristol, Canynge Hall</institution> Whiteladies Road, Bristol BS8 2PR, <country>UK</country></aff><aff id="aff8"><label>8</label><institution>Academic Urology Unit, University of Sheffield</institution> Sheffield S10 2JF, <country>UK</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Rosalind.Eeles@icr.ac.uk">Rosalind.Eeles@icr.ac.uk</email></corresp><corresp id="caf2"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Zsofia.Kote-Jarai@icr.ac.uk">Zsofia.Kote-Jarai@icr.ac.uk</email></corresp><fn fn-type="present-address" id="note1"><label>9</label><p>List available on request.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>01</month><year>2009</year></pub-date><pub-date pub-type="collection"><day>22</day><month>01</month><year>2009</year></pub-date><pub-date pub-type="ppub"><day>27</day><month>01</month><year>2009</year></pub-date><volume>100</volume><issue>2</issue><fpage>426</fpage><lpage>430</lpage><history><date date-type="received"><day>24</day><month>09</month><year>2008</year></date><date date-type="rev-recd"><day>01</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>01</day><month>12</month><year>2008</year></date></history><copyright-statement>Copyright 2009, Cancer Research UK</copyright-statement><copyright-year>2009</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>Although prostate cancer (PrCa) is one of the most common cancers in men in Western countries, little is known about the inherited factors that influence PrCa risk. On the basis of the fact that BRIP1/FANCJ interacts with BRCA1 and functions as a regulator of DNA double-strand break repair pathways, and that germline mutations within the <italic>BRIP1/FANCJ</italic> gene predispose to breast cancer, we chose this gene as a candidate for mutation screening in familial and young-onset PrCa cases. We identified a truncating mutation, R798X, in the <italic>BRIP1/FANCJ</italic> gene in 4 out of 2714 UK PrCa cases enriched for familial (2 out of 641; 0.3&#x00025;) and young-onset cases (2 out of 2073; 0.1&#x00025;). On screening 2045 controls from the UK population, we found one R798X sequence alteration (0.05&#x00025;; odds ratio 2.4 (95&#x00025; CI 0.25&#x02013;23.4)). In addition, using our data from a genome-wide association study, we analysed 25 SNPs in the genomic region of the <italic>BRIP1</italic>/<italic>FANCJ</italic> gene. Two SNPs showed evidence of association with familial and young-onset PrCa (rs6504074; <italic>P</italic><sub>trend</sub>=0.04 and rs8076727; <italic>P</italic><sub>trend</sub>=0.01). These results suggest that truncating mutations in <italic>BRIP1</italic>/<italic>FANCJ</italic> might confer an increased risk of PrCa and common SNPs might also contribute to the alteration of risk, but larger case&#x02013;control series will be required to confirm or refute this association.</p></abstract><kwd-group><kwd>prostate cancer predisposition</kwd><kwd><italic>FANCJ/BRIP1</italic></kwd><kwd>deleterious mutation</kwd><kwd>SNPs</kwd></kwd-group></article-meta></front><body><p>Prostate cancer (PrCa) aggregates in families, in a consistent manner with an important inherited component (reviewed in <xref ref-type="other" rid="bib8">Edwards and Eeles, 2004</xref>). The genetic components underlying this familial risk have, however, proved difficult to identify. Genetic studies using linkage analysis in high-risk families have identified several possible susceptibility loci (<xref ref-type="other" rid="bib17">Tavtigian <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib4">Carpten <italic>et al</italic>, 2002</xref>), but none of them have been definitively established (<xref ref-type="other" rid="bib7">Easton <italic>et al</italic>, 2003</xref>). It seems likely now that susceptibility to PrCa is mediated, at least partially, through a combination of multiple low-penetrance loci (<xref ref-type="other" rid="bib13">Haiman <italic>et al</italic>, 2007</xref>; <xref ref-type="other" rid="bib10">Eeles <italic>et al</italic>, 2008</xref>; <xref ref-type="other" rid="bib18">Thomas <italic>et al</italic>, 2008</xref>).</p><p>Genome-wide association studies (GWAS) have identified common variants in several regions that are associated with PrCa risk (<xref ref-type="other" rid="bib10">Eeles <italic>et al</italic>, 2008</xref>; <xref ref-type="other" rid="bib11">Gudmundsson <italic>et al</italic>, 2008</xref>; <xref ref-type="other" rid="bib18">Thomas <italic>et al</italic>, 2008</xref>). In addition, resequencing of candidate genes, notably those involved in DNA double-strand break repair, has identified rarer variants associated with a more substantial risk. The most important of these is <italic>BRCA2</italic> mutations, which confer a risk of approximately five-fold, but there is evidence that truncating mutations in <italic>NBS1</italic> and <italic>CHEK2</italic> also confer susceptibility to PrCa (<xref ref-type="other" rid="bib6">Dong <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib9">Edwards <italic>et al</italic>, 2003</xref>; <xref ref-type="other" rid="bib5">Cybulski <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib1">Agalliu <italic>et al</italic>, 2007</xref>).</p><p>The <italic>BRIP1</italic>/<italic>FANCJ</italic> gene encodes a helicase in which the C-terminal domain is reported to interact with BRCA1 (<xref ref-type="other" rid="bib3">Cantor <italic>et al</italic>, 2001</xref>). The <italic>BRIP1</italic> gene spans 180&#x02009;kb, comprises 20 exons and encodes a protein of 1249 amino acids. It is located on chromosome 17q22, distal to <italic>BRCA1</italic>, which is at 17q21. BRIP1/FANCJ has an important role in BRCA-associated DNA damage repair functions, works as a DNA-dependent ATPase and a DNA helicase, and is essential for DNA repair and genomic stability. It forms a complex with the BRCT domain of BRCA1, and this is important for the role of BRCA1 in its DNA double-strand break repair function (<xref ref-type="other" rid="bib14">Levitus <italic>et al</italic>, 2006</xref>).</p><p>Germline mutations in <italic>BRIP1/FANCJ</italic> are associated with Fanconi anaemia, a chromosomal instability syndrome characterised by developmental abnormalities and predisposition to cancer (<xref ref-type="other" rid="bib15">Levitus <italic>et al</italic>, 2005</xref>). Truncating mutations in the <italic>BRIP1/FANCJ</italic> gene have recently been shown to be associated with a moderate risk of breast cancer (<xref ref-type="other" rid="bib16">Seal <italic>et al</italic>, 2006</xref>). Given the observed associations of PrCa with other DNA repair genes, we considered <italic>BRIP1/FANCJ</italic> as an attractive candidate for PrCa-predisposition gene.</p><sec sec-type="materials|methods"><title>Materials and methods</title><p>Whole blood samples from PrCa cases were collected as part of the UK Genetic Prostate Cancer Study (UKGPCS), a national study of familial and young cases of PrCa. Familial samples were from 192 cases with two affected relatives (&#x02018;strong family history') and 449 other samples with one affected relative (&#x02018;some family history'). One person per family was used for sequence analysis. Wherever possible, the youngest affected family member was considered. Young-onset cases comprised 2073 men with a diagnosis of PrCa at age &#x02a7d;60 years. All self-reported non-Caucasians were excluded. The study was approved by the multiregional ethics committee and all patients gave informed consent. All PrCa diagnosis was based on the verification of the histological report or death certificate.</p><p>Caucasian controls comprised 2045 blood DNA samples, which were selected through the ProtecT study. ProtecT is a national study of community-based PSA testing and a randomised trial of subsequent PrCa treatment. Men between the ages of 50 and 69 years are recruited through general practices in nine centres in the UK. Ethnically matched controls were sampled from these centres to match approximately the geographical distribution of the cases. DNA was extracted using standard methods as described in <xref ref-type="other" rid="bib10">Eeles <italic>et al</italic> (2008)</xref>.</p><p>The full coding sequence and exon&#x02013;intron boundaries of the 192 familial samples were analysed by sequencing. The sequencing was carried out using the BigDyeTerminator v3.2 Cycle Sequencing kit and the 3700 automated sequencer (Applied Biosystems, Foster City, CA, USA).</p><p>All the additional samples, 2073 young-onset cases and 2045 UK population controls were tested for the R798X sequence variant by the 5&#x02032;nuclease assay (Taqman&#x02122;) using the ABIPrism 7900HT sequence detection system according to the manufacturer's instructions. Primers and probes were supplied directly by Applied Biosystems (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.appliedbiosystems.com/">http://www.appliedbiosystems.com/</ext-link>) as Assays-By-Design&#x02122;.</p><p>We had earlier carried out a GWAS, involving 1854 of the PrCa cases and 1894 controls using the Illumina Infinium HumanHap550 array (<xref ref-type="other" rid="bib10">Eeles <italic>et al</italic>, 2008</xref>). From these data, we identified 25 SNPs from the 270-kb region covering the genomic sequences of <italic>BRIP1/FANCJ,</italic> which were used to obtain evidence for associations between common variants and PrCa risk.</p><p>Significance tests, odds ratios (ORs) and confidence limits were computed using standard methods. For the SNPs, both Cochran&#x02013;Armitage trend tests and 2-degrees-of-freedom tests were calculated. For Hardy&#x02013;Weinberg equilibrium and Armitage trend testing, we used the public software developed by Tim M Strom and Thomas F Wienker (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ihg.gsf.de/cgi-bin/hw/hwa1.pl">http://ihg.gsf.de/cgi-bin/hw/hwa1.pl</ext-link>).</p></sec><sec><title>Results</title><p>Initially, a set of genomic DNA samples representing the youngest affected individual from 192 multiple case PrCa families was screened. The full coding sequence and exon&#x02013;intron boundaries of the <italic>BRIP1</italic>/<italic>FANCJ</italic> were analysed by sequencing. A truncating mutation, R798X (1 out of 192, 0.52&#x00025;) was identified in the proband from a family with three affected brothers (<xref rid="tbl1" ref-type="table">Table 1</xref>). The pedigree and the result of the segregation analysis are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. The available blood samples were tested for this germline mutation and one affected brother carried the mutation, whereas the unaffected brother did not. Only a paraffin-embedded tissue sample (biopsy) was available from the third affected brother, and sequencing the DNA sample from this did not show the mutation. Blood samples from his three sons were also tested and were all found to be non-carriers for the R798X mutation. In addition to this deleterious mutation, several missense mutations were identified in the 192 familial samples, as presented in <xref rid="tbl2" ref-type="table">Table 2</xref>. No other mutations that were predicted to truncate the protein were identified.</p><p>To establish the contribution of the <italic>BRIP1</italic>/<italic>FANCJ</italic> R798X mutation to PrCa predisposition, we screened a further 449 samples with a single affected relative and 2073 young-onset PrCa cases, (individuals diagnosed with PrCa before 60 years of age with no family history) and 2045 controls. The R798X mutation was present in two of the young-onset cases (0.10&#x00025;), in one of the familial cases (0.22&#x00025;), and in one of the controls (0.05&#x00025;) (<xref rid="tbl1" ref-type="table">Table 1</xref>). The ages of onset of the mutation carriers were 49 and 60 years. Neither case had a family history of PrCa. However, one of these mutation carriers had a family history of other cancers and malformations, which appear characteristic of Gorlin syndrome. The familial case had one affected second-degree relative with an unknown age of onset, and also had relatives affected with other cancers (colon and stomach cancer).</p><p>On the basis of our data, the estimated OR for PrCa was 2.4 (95&#x00025; CI 0.25&#x02013;23.4). If the control data of <xref ref-type="other" rid="bib16">Seal <italic>et al</italic> (2006)</xref> are also considered in our analysis, the estimate is somewhat more precise (OR 2.5, 95&#x00025; CI 0.41&#x02013;14.7) but still not significantly different from 1.</p><p>We found five other amino-acid substitutions in the 192 familial samples sequenced (<xref rid="tbl2" ref-type="table">Table 2</xref>). All have been reported earlier (<xref ref-type="other" rid="bib16">Seal <italic>et al</italic>, 2006</xref>; <xref ref-type="other" rid="bib12">Gu&#x000e9;nard <italic>et al</italic>, 2008</xref>). All of these sequence variants were also found in the control series. The common variant p.Pro919Ser showed some evidence of an association with risk (<italic>P</italic><sub>trend</sub>=0.034) in this set of cases with strong family history. However, this SNP (rs4986764) was also included on the Illumina 550k array used in our GWAS (<xref ref-type="other" rid="bib10">Eeles <italic>et al</italic>, 2008</xref>). In this larger study of familial and young-onset cases there was no evidence of association with PrCa (<italic>P</italic><sub>trend</sub>=0.48). None of the four rare variants showed a difference in frequency between cases and controls.</p><p>We also analysed the genotype frequencies of 25 SNPs from the Illumina 550k array in the genomic region of <italic>FANCJ/BRIP1</italic> for 1853 PrCa cases and 1880 control individuals (<xref ref-type="other" rid="bib10">Eeles <italic>et al</italic>, 2008</xref>). We found significant differences in genotype frequencies between cases and controls for two SNPs: rs6504074 and rs8076727 (<xref rid="tbl3" ref-type="table">Table 3</xref>). The estimated per allele OR for rs6504074 was 1.10 (<italic>P</italic><sub>trend</sub>=0.029); this rose to 1.20 (<italic>P</italic><sub>trend</sub>=0.01) when the analysis was restricted to familial cases. The estimated OR for rs8076727 was 1.29 (<italic>P</italic>=0.01); this rose to 1.39 (<italic>P</italic>=0.01) for familial cases.</p></sec><sec><title>Discussion</title><p>We have identified a recurrent deleterious mutation in the <italic>BRIP1/FANCJ</italic> gene in a set of familial and young-onset PrCa cases.</p><p>This truncating mutation has been reported earlier in four Fanconi anaemia subtype J families of diverse geographic origin (<xref ref-type="other" rid="bib15">Levitus <italic>et al</italic>, 2005</xref>) and in five breast cancer families (<xref ref-type="other" rid="bib16">Seal <italic>et al</italic>, 2006</xref>), suggesting that it is a relatively ancient founder mutation. The frequency of this mutation in our control population is almost identical to that found in the study by <xref ref-type="other" rid="bib16">Seal <italic>et al</italic> (2006)</xref> (1 in 2081).</p><p>This recurrent R798X mutation in exon 17 predicts a truncated protein in which the helicase motif VI and the BRCA1 interacting regions are deleted. BRIP1/FANCJ binds directly to the C-terminal BRCA repeats of BRCA1 and this interaction is regulated in a cell-cycle-dependent manner. However, in the Fanconi anaemia pathway for DNA crosslink repair, BRIP1/FANCJ functions independently of this interaction (<xref ref-type="other" rid="bib2">Bridge <italic>et al</italic>, 2005</xref>).</p><p><italic>BRIP1</italic>/<italic>FANCJ</italic> encodes a DEAH-box helicase and can directly interact with DNA (<xref ref-type="other" rid="bib2">Bridge <italic>et al</italic>, 2005</xref>). It can unwind DNA structures such as Holliday junctions formed during homologous recombination, suggesting an association with some DNA repair processes (<xref ref-type="other" rid="bib14">Levitus <italic>et al</italic>, 2006</xref>). It is interesting that most of the Fanconi anaemia genes encode proteins that form a nuclear core complex with a function of monoubiquitination of FANCD2, but FANCD1 (BRCA2) and BRIP1/FANCJ function downstream of this and they both have a more defined role in DNA damage repair.</p><p>We have reported earlier that 2&#x00025; of men diagnosed with PrCa at &#x0003c;55 years had a germline mutation in the <italic>BRCA2</italic> gene (<xref ref-type="other" rid="bib9">Edwards <italic>et al</italic>, 2003</xref>)<italic>. BRCA2</italic> is a high-risk breast cancer predisposition gene and is also known as <italic>FANCD1</italic>, responsible for causing FA-D1. It is therefore plausible that truncating mutations in <italic>BRID1/FANCJ</italic> also predispose to PrCa. Our results for the R798X mutation are consistent with a moderate risk of PrCa, comparable to that for breast cancer, but larger numbers will be required to confirm this.</p><p>We found five other amino-acid substitutions in the 192 familial samples sequenced (<xref rid="tbl2" ref-type="table">Table 2</xref>), all of which have been reported earlier (<xref ref-type="other" rid="bib16">Seal <italic>et al</italic>, 2006</xref>; <xref ref-type="other" rid="bib12">Gu&#x000e9;nard <italic>et al</italic>, 2008</xref>). Three of these variants are situated within the Rad3-related DNA helicase domain (res.1&#x02013;888) and one, the common p.Pro919Ser variant, is within the BRCA1-binding domain (<xref ref-type="other" rid="bib2">Bridge <italic>et al</italic>, 2005</xref>). The p.Arg173 is a strongly conserved residue in mammals, whereas the other variants are poorly conserved in other species (<xref ref-type="other" rid="bib12">Gu&#x000e9;nard <italic>et al</italic>, 2008</xref>). We found no evidence for significant association between these sequence variants and PrCa risk.</p><p>We have also evaluated the association between 25 common SNPs and the risk of PrCa in a case&#x02013;control design and found two SNPs significantly associated with PrCa risk. Both of the associated SNPs are in intron 6. These associations, although nominally significant, do not reach the stringent levels of significance appropriate for candidate gene or genome-wide scans, and could have occurred by chance. However, if verified in larger series, they could be markers for common variants in <italic>BRID1/FANCJ</italic> influencing the risk.</p><p>In conclusion, we report that deleterious mutations in <italic>BRIP1/FANCJ</italic> occur in a modest number of familial and young-onset PrCa cases. In addition, we found evidence of association with two common SNPs. These observations warrant further evaluation in independent case&#x02013;control studies.</p></sec></body><back><ack><p>We thank all the patients and control men who took part in this study. This work was supported by The Prostate Cancer Research Foundation and Cancer Research UK Grant C5047/A3354. DFE is a Principal Research Fellow of Cancer Research UK. We would also like to thank the following for funding: The Institute of Cancer Research and The Everyman Campaign, Prostate Research Campaign UK, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK and NHS funding to the NIHR Biomedical Research Centre. The ProtecT study is ongoing and is funded by the Health Technology Assessment Programme (projects 96/20/06, 96/20/99) and Cancer Research UK Grant Number C522/A8649. We would like to acknowledge the tremendous contribution of all members of the ProtecT study research group.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agalliu</surname><given-names>I</given-names></name><name><surname>Karlins</surname><given-names>E</given-names></name><name><surname>Kwon</surname><given-names>EM</given-names></name><name><surname>Iwasaki</surname><given-names>LM</given-names></name><name><surname>Diamond</surname><given-names>A</given-names></name><name><surname>Ostrander</surname><given-names>EA</given-names></name><name><surname>Stanford</surname><given-names>JL</given-names></name></person-group><article-title>Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer</article-title><source>Br J Cancer</source><year>2007</year><volume>97</volume><fpage>826</fpage><lpage>831</lpage><!--PubMed citation query: 'Br J Cancer||97|826||bib1|'--><pub-id pub-id-type="pmid">17700570</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bridge</surname><given-names>WL</given-names></name><name><surname>Vandenberg</surname><given-names>CJ</given-names></name><name><surname>Franklin</surname><given-names>RJ</given-names></name><name><surname>Hiom</surname><given-names>K</given-names></name></person-group><article-title>The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>953</fpage><lpage>957</lpage><!--PubMed citation query: 'Nat Genet||37|953||bib2|'--><pub-id pub-id-type="pmid">16116421</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>SB</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Kass</surname><given-names>EM</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Grossman</surname><given-names>S</given-names></name><name><surname>Wahrer</surname><given-names>DC</given-names></name><name><surname>Sgroi</surname><given-names>DC</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name></person-group><article-title>BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function</article-title><source>Cell</source><year>2001</year><volume>105</volume><fpage>149</fpage><lpage>160</lpage><!--PubMed citation query: 'Cell||105|149||bib3|'--><pub-id pub-id-type="pmid">11301010</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carpten</surname><given-names>J</given-names></name><name><surname>Nupponen</surname><given-names>N</given-names></name><name><surname>Isaacs</surname><given-names>S</given-names></name><name><surname>Sood</surname><given-names>R</given-names></name><name><surname>Robbins</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Faruque</surname><given-names>M</given-names></name><name><surname>Moses</surname><given-names>T</given-names></name><name><surname>Ewing</surname><given-names>C</given-names></name><name><surname>Gillanders</surname><given-names>E</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><name><surname>Bujnovszky</surname><given-names>P</given-names></name><name><surname>Makalowska</surname><given-names>I</given-names></name><name><surname>Baffoe-Bonnie</surname><given-names>A</given-names></name><name><surname>Faith</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Stephan</surname><given-names>D</given-names></name><name><surname>Wiley</surname><given-names>K</given-names></name><name><surname>Brownstein</surname><given-names>M</given-names></name><name><surname>Gildea</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>B</given-names></name><name><surname>Jenkins</surname><given-names>R</given-names></name><name><surname>Hostetter</surname><given-names>G</given-names></name><name><surname>Matikainen</surname><given-names>M</given-names></name><name><surname>Schleutker</surname><given-names>J</given-names></name><name><surname>Klinger</surname><given-names>K</given-names></name><name><surname>Connors</surname><given-names>T</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>De Marzo</surname><given-names>A</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Kallioniemi</surname><given-names>OP</given-names></name><name><surname>Burk</surname><given-names>R</given-names></name><name><surname>Meyers</surname><given-names>D</given-names></name><name><surname>Gr&#x000f6;nberg</surname><given-names>H</given-names></name><name><surname>Meltzer</surname><given-names>P</given-names></name><name><surname>Silverman</surname><given-names>R</given-names></name><name><surname>Bailey-Wilson</surname><given-names>J</given-names></name><name><surname>Walsh</surname><given-names>P</given-names></name><name><surname>Isaacs</surname><given-names>W</given-names></name><name><surname>Trent</surname><given-names>J</given-names></name></person-group><article-title>Germline mutations in the ribonuclease L gene in families showing linkage with HPC1</article-title><source>Nat Genet</source><year>2002</year><volume>30</volume><fpage>181</fpage><lpage>184</lpage><!--PubMed citation query: 'Nat Genet||30|181||bib4|'--><pub-id pub-id-type="pmid">11799394</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cybulski</surname><given-names>C</given-names></name><name><surname>G&#x000f3;rski</surname><given-names>B</given-names></name><name><surname>Debniak</surname><given-names>T</given-names></name><name><surname>Gliniewicz</surname><given-names>B</given-names></name><name><surname>Mierzejewski</surname><given-names>M</given-names></name><name><surname>Masoj&#x000e6;</surname><given-names>B</given-names></name><name><surname>Jakubowska</surname><given-names>A</given-names></name><name><surname>Matyjasik</surname><given-names>J</given-names></name><name><surname>Z&#x00142;owocka</surname><given-names>E</given-names></name><name><surname>Sikorski</surname><given-names>A</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Lubi&#x000f1;ski</surname><given-names>J</given-names></name></person-group><article-title>NBS1 is a prostate cancer susceptibility gene</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>1215</fpage><lpage>1219</lpage><!--PubMed citation query: 'Cancer Res||64|1215||bib5|'--><pub-id pub-id-type="pmid">14973119</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Taniguchi</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cunningham</surname><given-names>JM</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Marks</surname><given-names>AF</given-names></name><name><surname>Slager</surname><given-names>SL</given-names></name><name><surname>Peterson</surname><given-names>BJ</given-names></name><name><surname>Smith</surname><given-names>DI</given-names></name><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Tindall</surname><given-names>DJ</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name></person-group><article-title>Mutations in CHEK2 associated with prostate cancer risk</article-title><source>Am J Hum Genet</source><year>2003</year><volume>72</volume><fpage>270</fpage><lpage>280</lpage><!--PubMed citation query: 'Am J Hum Genet||72|270||bib6|'--><pub-id pub-id-type="pmid">12533788</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Whittemore</surname><given-names>AS</given-names></name><name><surname>Isaacs</surname><given-names>WJ</given-names></name><collab>International Consortium for Prostate Cancer Genetics</collab></person-group><article-title>Where are the prostate cancer genes? A summary of eight genome wide searches</article-title><source>Prostate</source><year>2003</year><volume>57</volume><fpage>261</fpage><lpage>269</lpage><!--PubMed citation query: 'Prostate||57|261||bib7|'--><pub-id pub-id-type="pmid">14601022</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>SM</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name></person-group><article-title>Unravelling the genetics of prostate cancer</article-title><source>Am J Med Genet C Semin Med Genet</source><year>2004</year><volume>129</volume><fpage>65</fpage><lpage>73</lpage><!--PubMed citation query: 'Am J Med Genet C Semin Med Genet||129|65||bib8|'--></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>SM</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Meitz</surname><given-names>J</given-names></name><name><surname>Hamoudi</surname><given-names>R</given-names></name><name><surname>Hope</surname><given-names>Q</given-names></name><name><surname>Osin</surname><given-names>P</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Southgate</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Falconer</surname><given-names>A</given-names></name><name><surname>Dearnaley</surname><given-names>DP</given-names></name><name><surname>Ardern-Jones</surname><given-names>A</given-names></name><name><surname>Murkin</surname><given-names>A</given-names></name><name><surname>Dowe</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Oram</surname><given-names>R</given-names></name><name><surname>Stevens</surname><given-names>M</given-names></name><name><surname>Teare</surname><given-names>DM</given-names></name><name><surname>Ponder</surname><given-names>BA</given-names></name><name><surname>Gayther</surname><given-names>SA</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><collab>Cancer Research UK/British Prostate Group UK Familial Prostate Cancer Study Collaborators, British Association of Urological Surgeons Section of Oncology</collab></person-group><article-title>Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene</article-title><source>Am J Hum Genet</source><year>2003</year><volume>72</volume><fpage>1</fpage><lpage>12</lpage><!--PubMed citation query: 'Am J Hum Genet||72|1||bib9|'--><pub-id pub-id-type="pmid">12474142</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Olama</surname><given-names>AA</given-names></name><name><surname>Guy</surname><given-names>M</given-names></name><name><surname>Jugurnauth</surname><given-names>SK</given-names></name><name><surname>Mulholland</surname><given-names>S</given-names></name><name><surname>Leongamornlert</surname><given-names>DA</given-names></name><name><surname>Edwards</surname><given-names>SM</given-names></name><name><surname>Morrison</surname><given-names>J</given-names></name><name><surname>Field</surname><given-names>HI</given-names></name><name><surname>Southey</surname><given-names>MC</given-names></name><name><surname>Severi</surname><given-names>G</given-names></name><name><surname>Donovan</surname><given-names>JL</given-names></name><name><surname>Hamdy</surname><given-names>FC</given-names></name><name><surname>Dearnaley</surname><given-names>DP</given-names></name><name><surname>Muir</surname><given-names>KR</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Bagnato</surname><given-names>M</given-names></name><name><surname>Ardern-Jones</surname><given-names>AT</given-names></name><name><surname>Hall</surname><given-names>AL</given-names></name><name><surname>O'Brien</surname><given-names>LT</given-names></name><name><surname>Gehr-Swain</surname><given-names>BN</given-names></name><name><surname>Wilkinson</surname><given-names>RA</given-names></name><name><surname>Cox</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>PM</given-names></name><name><surname>Jhavar</surname><given-names>SG</given-names></name><name><surname>Tymrakiewicz</surname><given-names>M</given-names></name><name><surname>Lophatananon</surname><given-names>A</given-names></name><name><surname>Bryant</surname><given-names>SL</given-names></name><name><surname>Horwich</surname><given-names>A</given-names></name><name><surname>Huddart</surname><given-names>RA</given-names></name><name><surname>Khoo</surname><given-names>VS</given-names></name><name><surname>Parker</surname><given-names>CC</given-names></name><name><surname>Woodhouse</surname><given-names>CJ</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Christmas</surname><given-names>T</given-names></name><name><surname>Ogden</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Jamieson</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>CS</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Neal</surname><given-names>DE</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><collab>UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators</collab></person-group><article-title>Multiple newly identified loci associated with prostate cancer susceptibility</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>316</fpage><lpage>321</lpage><!--PubMed citation query: 'Nat Genet||40|316||bib10|'--><pub-id pub-id-type="pmid">18264097</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Bergthorsson</surname><given-names>JT</given-names></name><name><surname>Manolescu</surname><given-names>A</given-names></name><name><surname>Gudbjartsson</surname><given-names>D</given-names></name><name><surname>Agnarsson</surname><given-names>BA</given-names></name><name><surname>Sigurdsson</surname><given-names>A</given-names></name><name><surname>Benediktsdottir</surname><given-names>KR</given-names></name><name><surname>Blondal</surname><given-names>T</given-names></name><name><surname>Jakobsdottir</surname><given-names>M</given-names></name><name><surname>Stacey</surname><given-names>SN</given-names></name><name><surname>Kostic</surname><given-names>J</given-names></name><name><surname>Kristinsson</surname><given-names>KT</given-names></name><name><surname>Birgisdottir</surname><given-names>B</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Magnusdottir</surname><given-names>DN</given-names></name><name><surname>Thorlacius</surname><given-names>S</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>SL</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>BL</given-names></name><name><surname>Elmore</surname><given-names>JB</given-names></name><name><surname>Breyer</surname><given-names>JP</given-names></name><name><surname>McReynolds</surname><given-names>KM</given-names></name><name><surname>Bradley</surname><given-names>KM</given-names></name><name><surname>Yaspan</surname><given-names>BL</given-names></name><name><surname>Wiklund</surname><given-names>F</given-names></name><name><surname>Stattin</surname><given-names>P</given-names></name><name><surname>Lindstr&#x000f6;m</surname><given-names>S</given-names></name><name><surname>Adami</surname><given-names>HO</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Cunningham</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cerhan</surname><given-names>JR</given-names></name><name><surname>St Sauver</surname><given-names>JL</given-names></name><name><surname>Isaacs</surname><given-names>SD</given-names></name><name><surname>Wiley</surname><given-names>KE</given-names></name><name><surname>Partin</surname><given-names>AW</given-names></name><name><surname>Walsh</surname><given-names>PC</given-names></name><name><surname>Polo</surname><given-names>S</given-names></name><name><surname>Ruiz-Echarri</surname><given-names>M</given-names></name><name><surname>Navarrete</surname><given-names>S</given-names></name><name><surname>Fuertes</surname><given-names>F</given-names></name><name><surname>Saez</surname><given-names>B</given-names></name><name><surname>Godino</surname><given-names>J</given-names></name><name><surname>Weijerman</surname><given-names>PC</given-names></name><name><surname>Swinkels</surname><given-names>DW</given-names></name><name><surname>Aben</surname><given-names>KK</given-names></name><name><surname>Witjes</surname><given-names>JA</given-names></name><name><surname>Suarez</surname><given-names>BK</given-names></name><name><surname>Helfand</surname><given-names>BT</given-names></name><name><surname>Frigge</surname><given-names>ML</given-names></name><name><surname>Kristjansson</surname><given-names>K</given-names></name><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Jonsson</surname><given-names>E</given-names></name><name><surname>Einarsson</surname><given-names>GV</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gronberg</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>JR</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Catalona</surname><given-names>WJ</given-names></name><name><surname>Mayordomo</surname><given-names>JI</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name><name><surname>Gulcher</surname><given-names>JR</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><article-title>Common sequence variants on 2p15 and Xp11@22 confer susceptibility to prostate cancer</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>281</fpage><lpage>283</lpage><!--PubMed citation query: 'Nat Genet||40|281||bib11|'--><pub-id pub-id-type="pmid">18264098</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu&#x000e9;nard</surname><given-names>F</given-names></name><name><surname>Labrie</surname><given-names>Y</given-names></name><name><surname>Ouellette</surname><given-names>G</given-names></name><name><surname>Joly Beauparlant</surname><given-names>C</given-names></name><name><surname>Simard</surname><given-names>J</given-names></name><name><surname>Durocher</surname><given-names>F</given-names></name><collab>INHERIT BRCAs</collab></person-group><article-title>Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families</article-title><source>J Hum Genet</source><year>2008</year><volume>53</volume><fpage>579</fpage><lpage>591</lpage><!--PubMed citation query: 'J Hum Genet||53|579||bib12|'--><pub-id pub-id-type="pmid">18414782</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Patterson</surname><given-names>N</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name><name><surname>Myers</surname><given-names>SR</given-names></name><name><surname>Pike</surname><given-names>MC</given-names></name><name><surname>Waliszewska</surname><given-names>A</given-names></name><name><surname>Neubauer</surname><given-names>J</given-names></name><name><surname>Tandon</surname><given-names>A</given-names></name><name><surname>Schirmer</surname><given-names>C</given-names></name><name><surname>McDonald</surname><given-names>GJ</given-names></name><name><surname>Greenway</surname><given-names>SC</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Frasco</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Pooler</surname><given-names>LC</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Oakley-Girvan</surname><given-names>I</given-names></name><name><surname>Whittemore</surname><given-names>AS</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>John</surname><given-names>EM</given-names></name><name><surname>Ingles</surname><given-names>SA</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Reich</surname><given-names>D</given-names></name></person-group><article-title>Multiple regions within 8q24 independently affect risk for prostate cancer</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>638</fpage><lpage>644</lpage><!--PubMed citation query: 'Nat Genet||39|638||bib13|'--><pub-id pub-id-type="pmid">17401364</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levitus</surname><given-names>M</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name><name><surname>de Winter</surname><given-names>JP</given-names></name></person-group><article-title>The Fanconi anemia pathway of genomic maintenance</article-title><source>Cell Oncol</source><year>2006</year><volume>28</volume><fpage>3</fpage><lpage>29</lpage><!--PubMed citation query: 'Cell Oncol||28|3||bib14|'--><pub-id pub-id-type="pmid">16675878</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levitus</surname><given-names>M</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>Godthelp</surname><given-names>BC</given-names></name><name><surname>de Vries</surname><given-names>Y</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Wiegant</surname><given-names>WW</given-names></name><name><surname>Elghalbzouri-Maghrani</surname><given-names>E</given-names></name><name><surname>Steltenpool</surname><given-names>J</given-names></name><name><surname>Rooimans</surname><given-names>MA</given-names></name><name><surname>Pals</surname><given-names>G</given-names></name><name><surname>Arwert</surname><given-names>F</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><name><surname>Zdzienicka</surname><given-names>MZ</given-names></name><name><surname>Hiom</surname><given-names>K</given-names></name><name><surname>De Winter</surname><given-names>JP</given-names></name><name><surname>Joenje</surname><given-names>H</given-names></name></person-group><article-title>The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>934</fpage><lpage>935</lpage><!--PubMed citation query: 'Nat Genet||37|934||bib15|'--><pub-id pub-id-type="pmid">16116423</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Renwick</surname><given-names>A</given-names></name><name><surname>Elliott</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>P</given-names></name><name><surname>Barfoot</surname><given-names>R</given-names></name><name><surname>Chagtai</surname><given-names>T</given-names></name><name><surname>Jayatilake</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Spanova</surname><given-names>K</given-names></name><name><surname>North</surname><given-names>B</given-names></name><name><surname>McGuffog</surname><given-names>L</given-names></name><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Eccles</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><collab>Breast Cancer Susceptibility Collaboration (UK)</collab></person-group><article-title>Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>1239</fpage><lpage>1241</lpage><!--PubMed citation query: 'Nat Genet||38|1239||bib16|'--><pub-id pub-id-type="pmid">17033622</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tavtigian</surname><given-names>SV</given-names></name><name><surname>Simard</surname><given-names>J</given-names></name><name><surname>Teng</surname><given-names>DH</given-names></name><name><surname>Abtin</surname><given-names>V</given-names></name><name><surname>Baumgard</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>A</given-names></name><name><surname>Camp</surname><given-names>NJ</given-names></name><name><surname>Carillo</surname><given-names>AR</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dayananth</surname><given-names>P</given-names></name><name><surname>Desrochers</surname><given-names>M</given-names></name><name><surname>Dumont</surname><given-names>M</given-names></name><name><surname>Farnham</surname><given-names>JM</given-names></name><name><surname>Frank</surname><given-names>D</given-names></name><name><surname>Frye</surname><given-names>C</given-names></name><name><surname>Ghaffari</surname><given-names>S</given-names></name><name><surname>Gupte</surname><given-names>JS</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Iliev</surname><given-names>D</given-names></name><name><surname>Janecki</surname><given-names>T</given-names></name><name><surname>Kort</surname><given-names>EN</given-names></name><name><surname>Laity</surname><given-names>KE</given-names></name><name><surname>Leavitt</surname><given-names>A</given-names></name><name><surname>Leblanc</surname><given-names>G</given-names></name><name><surname>McArthur-Morrison</surname><given-names>J</given-names></name><name><surname>Pederson</surname><given-names>A</given-names></name><name><surname>Penn</surname><given-names>B</given-names></name><name><surname>Peterson</surname><given-names>KT</given-names></name><name><surname>Reid</surname><given-names>JE</given-names></name><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Snyder</surname><given-names>SC</given-names></name><name><surname>Swedlund</surname><given-names>B</given-names></name><name><surname>Swensen</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Tranchant</surname><given-names>M</given-names></name><name><surname>Woodland</surname><given-names>AM</given-names></name><name><surname>Labrie</surname><given-names>F</given-names></name><name><surname>Skolnick</surname><given-names>MH</given-names></name><name><surname>Neuhausen</surname><given-names>S</given-names></name><name><surname>Rommens</surname><given-names>J</given-names></name><name><surname>Cannon-Albright</surname><given-names>LA</given-names></name></person-group><article-title>A candidate prostate cancer susceptibility gene at chromosome 17p</article-title><source>Nat Genet</source><year>2001</year><volume>27</volume><fpage>172</fpage><lpage>180</lpage><!--PubMed citation query: 'Nat Genet||27|172||bib17|'--><pub-id pub-id-type="pmid">11175785</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Jacobs</surname><given-names>KB</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Orr</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Chatterjee</surname><given-names>N</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><name><surname>Crenshaw</surname><given-names>A</given-names></name><name><surname>Cancel-Tassin</surname><given-names>G</given-names></name><name><surname>Staats</surname><given-names>BJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gonzalez-Bosquet</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Calle</surname><given-names>EE</given-names></name><name><surname>Feigelson</surname><given-names>HS</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name><name><surname>Rodriguez</surname><given-names>C</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Virtamo</surname><given-names>J</given-names></name><name><surname>Weinstein</surname><given-names>S</given-names></name><name><surname>Schumacher</surname><given-names>FR</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Cussenot</surname><given-names>O</given-names></name><name><surname>Valeri</surname><given-names>A</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name><name><surname>Tucker</surname><given-names>M</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Hoover</surname><given-names>R</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name></person-group><article-title>Multiple loci identified in a genome-wide association study of prostate cancer</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>310</fpage><lpage>315</lpage><!--PubMed citation query: 'Nat Genet||40|310||bib18|'--><pub-id pub-id-type="pmid">18264096</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Prostate cancer (PC) family with the R798X nonsense mutation in <italic>BRIP1/FANCJ.</italic> Wild-type (WT) labels on individuals tested but non-carriers of R798X, Leu=leukaemia, SC=stomach cancer. (The pedigree has been modified to maintain confidentiality.)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="6604847f1"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Recurring mutation in <italic>BRIP1</italic>/<italic>FANCJ</italic> in prostate cancer</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Mutation</bold></th><th align="left" valign="top" charoff="50"><bold>Study group</bold></th><th align="center" valign="top" charoff="50"><bold>No. of samples screened</bold></th><th align="center" valign="top" charoff="50"><bold>No. of mutations</bold></th><th align="center" valign="top" charoff="50"><bold>Frequency</bold></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">p.Arg798Stop R798X</td><td align="left" valign="top" charoff="50">Cases with strong family history (proband from families of three or more PrCa)</td><td align="center" valign="top" charoff="50">192</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0.52 &#x00025;</td><td align="center" valign="top" charoff="50">0.16</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Cases with some family history (proband from families of two PrCa)</td><td align="center" valign="top" charoff="50">449</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0.22&#x00025;</td><td align="center" valign="top" charoff="50">0.33</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Young-onset cases (diagnosed at &#x02a7d;60 years of age)</td><td align="center" valign="top" charoff="50">2073</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">0.10&#x00025;</td><td align="center" valign="top" charoff="50">0.51</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">All young-onset or familial PrCa tested</td><td align="center" valign="top" charoff="50">2714</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">0.14&#x00025;</td><td align="center" valign="top" charoff="50">0.29</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">UK population controls</td><td align="center" valign="top" charoff="50">2045</td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">0.05&#x00025;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><label/><p>PrCa=prostate cancer.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Non-synonymous sequence variants found in <italic>BRIP1</italic>/<italic>FANCJ</italic> in familial PrCa</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>Cases, <italic>n</italic> (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Controls<sup>a</sup>, <italic>n</italic> (&#x00025;)</bold></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Exon</bold></th><th align="left" valign="top" charoff="50"><bold>Nucleotide change</bold></th><th align="left" valign="top" charoff="50"><bold>dbSNP ID</bold></th><th colspan="2" align="left" valign="top" charoff="50"><bold>Protein change</bold></th><th align="center" valign="top" charoff="50"><bold><italic>n</italic>=192</bold></th><th align="center" valign="top" charoff="50"><bold><italic>n</italic>=2081</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">c.517C&#x0003e;T</td><td align="left" valign="top" charoff="50">rs4988345</td><td align="left" valign="top" charoff="50">p.Arg173Cys</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1 (0.52&#x00025;)</td><td align="center" valign="top" charoff="50">24 (1.10&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">c.577G&#x0003e;A</td><td align="left" valign="top" charoff="50">rs4988346</td><td align="left" valign="top" charoff="50">p.Val193Ile</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">1 (0.52&#x00025;)</td><td align="center" valign="top" charoff="50">14 (0.67&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">c.584T&#x0003e;C</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">p.Leu195Pro</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">2 (1.04&#x00025;)</td><td align="center" valign="top" charoff="50">6 (0.28&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">7</td><td align="left" valign="top" charoff="50">c.890A&#x0003e;G</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">p.Lys297Arg</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">2 (1.04&#x00025;)</td><td align="center" valign="top" charoff="50">6 (0.28&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">19</td><td align="left" valign="top" charoff="50">c.2755C&#x0003e;T</td><td align="left" valign="top" charoff="50">rs4986764</td><td align="left" valign="top" charoff="50">p.Pro919Ser</td><td align="center" valign="top" charoff="50">Pro/Ser</td><td align="center" valign="top" charoff="50">83 (43.00&#x00025;)</td><td align="center" valign="top" charoff="50">970 (46.0&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">Ser/Ser</td><td align="center" valign="top" charoff="50">44 (22.9&#x00025;)</td><td align="center" valign="top" charoff="50">328 (15.7&#x00025;)</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label/><p>PrCa=prostate cancer.</p></fn><fn id="t2-fn2"><label>a</label><p>Data from <xref ref-type="other" rid="bib16">Seal <italic>et al</italic> (2006)</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Prostate cancer genotype specific risk for two SNPs in <italic>BRIP1</italic>/<italic>FANCJ</italic> genomic region</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>GG</bold></th><th align="center" valign="top" charoff="50"><bold>TG</bold></th><th align="center" valign="top" charoff="50"><bold>TT</bold></th><th align="center" valign="top" charoff="50"><bold>Per allele OR (95&#x00025; CI)</bold></th><th align="center" valign="top" charoff="50"><bold>OR Hom (95&#x00025; CI)</bold></th><th align="center" valign="top" charoff="50"><bold>OR Het (95&#x00025; CI)</bold></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic><sub>Het</sub></bold></th><th align="center" valign="top" charoff="50"><bold><italic>P</italic><sub>trend</sub></bold></th></tr></thead><tbody valign="top"><tr><td colspan="9" align="left" valign="top" charoff="50"><italic>rs6504074</italic></td></tr><tr><td align="left" valign="top" charoff="50">Familial</td><td align="center" valign="top" charoff="50">345</td><td align="center" valign="top" charoff="50">274</td><td align="center" valign="top" charoff="50">64</td><td align="center" valign="top" charoff="50">1.20 (1.04&#x02013;1.37)</td><td align="center" valign="top" charoff="50">1.57 (1.13&#x02013;2.17)</td><td align="center" valign="top" charoff="50">1.13 (0.94&#x02013;1.35)</td><td align="center" valign="top" charoff="50">0.21</td><td align="center" valign="top" charoff="50">0.01</td></tr><tr><td align="left" valign="top" charoff="50">Young</td><td align="center" valign="top" charoff="50">618</td><td align="center" valign="top" charoff="50">453</td><td align="center" valign="top" charoff="50">87</td><td align="center" valign="top" charoff="50">1.07 (0.94&#x02013;1.20)</td><td align="center" valign="top" charoff="50">1.19 (0.89&#x02013;1.59)</td><td align="center" valign="top" charoff="50">1.04 (0.89&#x02013;1.21)</td><td align="center" valign="top" charoff="50">0.62</td><td align="center" valign="top" charoff="50">0.28</td></tr><tr><td align="left" valign="top" charoff="50">All</td><td align="center" valign="top" charoff="50">963</td><td align="center" valign="top" charoff="50">727</td><td align="center" valign="top" charoff="50">151</td><td align="center" valign="top" charoff="50">1.11 (1.00&#x02013;1.23)</td><td align="center" valign="top" charoff="50">1.33 (1.03&#x02013;1.71)</td><td align="center" valign="top" charoff="50">1.07 (0.94&#x02013;1.23)</td><td align="center" valign="top" charoff="50">0.32</td><td align="center" valign="top" charoff="50">0.04</td></tr><tr><td align="left" valign="top" charoff="50">Control</td><td align="center" valign="top" charoff="50">1031</td><td align="center" valign="top" charoff="50">727</td><td align="center" valign="top" charoff="50">122</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="9" align="left" valign="top" charoff="50"><italic>rs8076727</italic></td></tr><tr><td align="left" valign="top" charoff="50">Familial</td><td align="center" valign="top" charoff="50">373</td><td align="center" valign="top" charoff="50">261</td><td align="center" valign="top" charoff="50">46</td><td align="center" valign="top" charoff="50">1.20 (1.04&#x02013;1.38)</td><td align="center" valign="top" charoff="50">1.39 (0.96&#x02013;2.00)</td><td align="center" valign="top" charoff="50">1.21 (1.01&#x02013;1.46)</td><td align="center" valign="top" charoff="50">0.04</td><td align="center" valign="top" charoff="50">0.01</td></tr><tr><td align="left" valign="top" charoff="50">Young</td><td align="center" valign="top" charoff="50">658</td><td align="center" valign="top" charoff="50">432</td><td align="center" valign="top" charoff="50">72</td><td align="center" valign="top" charoff="50">1.12 (1.00&#x02013;1.27)</td><td align="center" valign="top" charoff="50">1.23 (0.90&#x02013;1.69)</td><td align="center" valign="top" charoff="50">1.14 (0.98&#x02013;1.33)</td><td align="center" valign="top" charoff="50">0.10</td><td align="center" valign="top" charoff="50">0.06</td></tr><tr><td align="left" valign="top" charoff="50">All</td><td align="center" valign="top" charoff="50">1031</td><td align="center" valign="top" charoff="50">693</td><td align="center" valign="top" charoff="50">118</td><td align="center" valign="top" charoff="50">1.13 (1.03&#x02013;1.28)</td><td align="center" valign="top" charoff="50">1.29 (0.97&#x02013;1.70)</td><td align="center" valign="top" charoff="50">1.17 (1.017&#x02013;1.336)</td><td align="center" valign="top" charoff="50">0.03</td><td align="center" valign="top" charoff="50">0.01</td></tr><tr><td align="left" valign="top" charoff="50">Control</td><td align="center" valign="top" charoff="50">1124</td><td align="center" valign="top" charoff="50">648</td><td align="center" valign="top" charoff="50">100</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><label/><p>OR=odds ratio; SNP=single nucleotide polymorphism.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>